Latest Breaking News On - Philippe cassier - Page 1 : comparemela.com

KAZIA PRESENTS NEW DATA FOR PAXALISIB AND EVT801 AT AACR ANNUAL MEETING

/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of.

United statesUnited kingdomNew south walesSalt lake cityUniversity of utahFrance generalGaelle badetKatie culverCharles eberhartMaxime battistellaAbigail tindallPierre benoit anceyHyuk jean kwonLise davenneJean pierre delordKristen malebranche

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023

Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesFrance generalCristina smolenschiImmunomodulatory therapiesposterLucie larguierLucas waltherChristelle demeusoitXavier noirielLuis mansoBrandon maloneNathalie silvestreMaud brandelyBenoit grellierTransgene euronextChristianh ottensmeierAnnette tavernaro

Transgene Confirms the Potential of the Intravenous Route of its Invir IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

Transgene Confirms the Potential of the Intravenous Route of its Invir IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalEmiliano calvoLucie larguierCarlos gomez rocaSophie sainte croixRocio garcia carboneroPhilippe cassierAlain sadounChristiane jungelsTransgene euronextVictor morenoBernard dogerCorporate communicationsEuropean society for medical oncologyEuronext parisEuropean society

TWO ABSTRACTS AT AACR CONFERENCE PRESENT DETAILED STUDY DESIGN AND INNOVATIVE BIOMARKER STRATEGY FOR ONGOING PHASE I STUDY OF EVT801 IN ADVANCED CANCER

/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two.

United statesNew south walesMichael esquerreJoel tuyaretMichael fitzgeraldMarie mandron evotecPhilippe cassierMaha ayyoubPhilippe rochaixLise davennePierre benoit anceyClara maria scarlataNathalie delesque touchardMarie mandronCarlos gomez rocaChristophe caux

OSE Immunotherapeutics to Host Today a Virtual Immuno-Oncology R&D Day

R&D Day to highlight the Company’s strategy on its leading clinical programs and emerging firs-in-class portfolio in immuno-oncology;Presentations by leading clinicians to feature the latest data on Tedopi® and BI 765063.NANTES, France (BUSINESS WIRE) Regulatory News:OSE Immunotherapeutics (ISIN: FR0012127173; Mné.

Thomas guillotPhilippe cassierFlorence portejoieGuillaume van renterghemBenjamin besseDarren oplandNantes university hospitalOncologist at leon berard cancer center lyonLifesci communicationsBoehringer ingelheimClinical research at gustave roussy villejuifRegulatory newsClinical researchGustave roussyMedical oncologistLeon berard cancer center